61 research outputs found

    Data-driven modelling of biological multi-scale processes

    Full text link
    Biological processes involve a variety of spatial and temporal scales. A holistic understanding of many biological processes therefore requires multi-scale models which capture the relevant properties on all these scales. In this manuscript we review mathematical modelling approaches used to describe the individual spatial scales and how they are integrated into holistic models. We discuss the relation between spatial and temporal scales and the implication of that on multi-scale modelling. Based upon this overview over state-of-the-art modelling approaches, we formulate key challenges in mathematical and computational modelling of biological multi-scale and multi-physics processes. In particular, we considered the availability of analysis tools for multi-scale models and model-based multi-scale data integration. We provide a compact review of methods for model-based data integration and model-based hypothesis testing. Furthermore, novel approaches and recent trends are discussed, including computation time reduction using reduced order and surrogate models, which contribute to the solution of inference problems. We conclude the manuscript by providing a few ideas for the development of tailored multi-scale inference methods.Comment: This manuscript will appear in the Journal of Coupled Systems and Multiscale Dynamics (American Scientific Publishers

    Input estimation for extended-release formulations exemplified with exenatide

    Get PDF
    Estimating the in vivo absorption profile of a drug is essential when developing extended-release medications. Such estimates can be obtained by measuring plasma concentrations over time and inferring the absorption from a model of the drug’s pharmacokinetics. Of particular interest is to predict the bioavailability—the fraction of the drug that is absorbed and enters the systemic circulation. This paper presents a framework for addressing this class of estimation problems and gives advice on the choice of method. In parametric methods, a model is constructed for the absorption process, which can be difficult when the absorption has a complicated profile. Here, we place emphasis on non-parametric methods that avoid making strong assumptions about the absorption. A modern estimation method that can address very general input-estimation problems has previously been presented. In this method, the absorption profile is modeled as a stochastic process, which is estimated using Markov chain Monte Carlo techniques. The applicability of this method for extended-release formulation development is evaluated by analyzing a dataset of Bydureon, an injectable extended-release suspension formulation of exenatide, a GLP-1 receptor agonist for treating diabetes. This drug is known to have non-linear pharmacokinetics. Its plasma concentration profile exhibits multiple peaks, something that can make parametric modeling challenging, but poses no major difficulties for non-parametric methods. The method is also validated on synthetic data, exploring the effects of sampling and noise on the accuracy of the estimates

    Bayesian inference for stochastic differential mixed-effects models

    Get PDF
    PhD ThesisStochastic differential equations (SDEs) provide a natural framework for modelling intrinsic stochasticity inherent in many continuous-time physical processes. When such processes are observed in multiple individuals or experimental units, SDE driven mixed- effects models allow the quantification of both between and within individual variation. Performing Bayesian inference for such models, using discrete-time data that may be incomplete and subject to measurement error, is a challenging problem and is the focus of this thesis. Since, in general, no closed form expression exists for the transition densities of the SDE of interest, a widely adopted solution works with the Euler-Maruyama approximation, by replacing the intractable transition densities with Gaussian approximations. These approximations can be made arbitrarily accurate by introducing intermediate time-points between observations. Integrating over the uncertainty associated with the process at these time-points necessitates the use of computationally intensive algorithms such as Markov chain Monte Carlo (MCMC). We extend a recently proposed MCMC scheme to include the SDE driven mixed-effects framework. Key to the development of an e fficient inference scheme is the ability to generate discrete-time realisations of the latent process between observation times. Such realisations are typically termed diffusion bridges. By partitioning the SDE into two parts, one that accounts for nonlinear dynamics in a deterministic way, and another as a residual stochastic process, we develop a class of novel constructs that bridge the residual process via a linear approximation. In addition, we adapt a recently proposed construct to a partial and noisy observation regime. We compare the performance of each new construct with a number of existing approaches, using three applications: a simple birth-death process, a Lotka-Volterra model and a model for aphid growth. We incorporate the best performing bridge construct within an MCMC scheme to determine the posterior distribution of the model parameters. This methodology is then applied to synthetic data generated from a simple SDE model of orange tree growth, and real data consisting of observations on aphid numbers recorded under a variety of different treatment regimes. Finally, we provide a systematic comparison of our approach with an inference scheme based on a tractable approximation of the SDE, that is, the linear noise approximatio

    STUDY DESIGN AND METHODS FOR EVALUATING SUSTAINED UNRESPONSIVENESS TO PEANUT SUBLINGUAL IMMUNOTHERAPY

    Get PDF
    The length of time off-therapy that would represent clinically meaningful sustained unresponsiveness (SU) to peanut allergen remains undefined. Our work has three-fold objectives: first, to delineate aspects of the altered clinical trial design that would allow us to assess effectiveness of sublingual immunotherapy (SLIT) in achieving SU; second, to discuss methodology for evaluating the time to loss of SU and associated risk factors in context of the proposed study design; finally, to develop a flexible methodology for assessing mean reverting threshold and prognosis of SU failure in the presence of study risk factors. Failure refers to the loss of SU upon therapy cessation in peanut allergic children who are administered sublingual immunotherapy (SLIT). The salient feature of the new design is the allocation scheme of study subjects to staggered sampling timepoints following therapy suspension when a subsequent food challenge is administered. Due to a fixed sequence of increasing allergen doses administered in a challenge-test, the subject’s true threshold at either occasion is interval-censored. Additionally, due to the timing of subsequent DBPCFC, the time to loss of SU for subjects who pass the DBPCFC at study entry is either left- or right-censored. In this thesis, we elaborate on the features of the study design, develop and extensively validate methods to evaluate study end points and discuss their potential to inform individualized treatments. The thesis is compartmentalized as follows: (i) an innovative clinical trial design that aims at studying SU to SLIT; (ii) a newly developed mixture proportional hazards model for evaluating the time to loss of SU in context of the study generated interval-censored data subject to instantaneous failures; (iii) a time-dependent Ornstein Uhlenbeck (OU) diffusion process for modeling immunologic SU degradation trajectories using stochastic differential mixed effect model (SDMEM) framework; (iv) the estimation of mean-reverting threshold and prognosis of the loss of SU; (v) lastly, the clinical implementation and future scope of work. Through this work, we are presented with an opportunity to dedicate these inter-connected parts to three core issues of failure: model description, prediction and prevention.Doctor of Public Healt

    Model Based Analysis of Ethnic Differences in Type 2 Diabetes

    Get PDF
    corecore